Gronghui, May 10, Canada Gakos-B (01167Callbreaksignupbonus.HK) announcementCallbreaksignupbonusThe company's independently developed KRASG12C inhibitor Glecirasib (JAB-21822) combined with epidermal growth factor receptor (anti-EGFR antibody) inhibitor ERBITUX ®(cetuximab) in the treatment of KRASG12C mutant colorectal cancer has been approved for phase III clinical trials in China.

The registered phase III clinical trial approved in ChinaCallbreaksignupbonusTo evaluate the efficacy and safety of Glecirasib combined with cetuximab in the treatment of unresectable or metastatic KRASG12C mutant colorectal cancer. In October 2022, Garcos entered into a clinical research partnership with Merck to conduct a clinical study on the combination of Glecirasib, an inhibitor of KRASG12C, and epidermal growth factor receptor (EGFR) inhibitor aribiturate (cetuximab injection). Based on the cooperation agreement, Merck provides cetuximab for Chinese and European joint drug trials.

In June 2023, Gakos presented the clinical data of Glecirasib combined with cetuximab in the treatment of advanced colorectal cancer with KRASG12C mutation at the second JCA-AACR International Conference on Precision Oncology Medicine (JCA-AACR Precision Cancer Medicine International Conference). In the clinical trial of Glecirasib combined with cetuximab, the objective remission rate (ORR) was 62.CallbreaksignupbonusThe disease control rate (DCR) was 93% (40 beat 43). According to the safety data, the treatment-related adverse events (TRAEs) of single and combined drugs were mainly grade 1-2.

Colorectal cancer is the second most common tumor in China, with about 550000 new cases each year, of which about 3% of colorectal cancer patients have KRASG12C mutations. Patients with KRASG12C mutant gene are not sensitive to the existing standard chemotherapy and targeted therapy, rapid disease progression, short survival time, and highly unmet clinical treatment needs. Glecirasib is expected to bring effective and less toxic treatment options for patients.